ClinicalTrials.gg

Program

Metformin

Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.

Furthest: phase 4, since Nov 9, 2005215 company-led studies, 7 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca290 open or runningphase 3since Nov 9, 2005Nov 9, 2005none ahead
Merck190 open or runningphase 4since Oct 9, 2009Feb 15, 2005none ahead
Sanofi160 open or runningphase 4since Jul 28, 2006Sep 30, 2002none ahead
GlaxoSmithKline140 open or runningphase 4since Oct 17, 2005Sep 3, 2003none ahead
Takeda120 open or runningphase 4since Sep 17, 2008Jul 30, 2008none ahead
Merck KGaA, Darmstadt, Germany90 open or runningphase 4since Dec 30, 2011Dec 30, 2011none ahead
Teva Pharmaceutical Industries90 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatris80 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
adium70 open or runningno phasesince Jun 3, 2026Jun 3, 2026none ahead
LG Chem70 open or runningphase 3since Feb 6, 2013Aug 22, 2011none ahead
Novartis70 open or runningphase 4since Aug 28, 2010Jul 31, 2008none ahead
elcelyx-therapeutics-inc60 open or runningphase 2since Aug 1, 2012Aug 1, 2012none ahead
Torrent Pharmaceuticals60 open or runningphase 1since Jul 21, 2009Jul 21, 2009none ahead
dong-wha-pharmaceutical-co-ltd50 open or runningphase 1since Aug 5, 2014Aug 5, 2014none ahead
Bristol-Myers Squibb40 open or runningphase 4since Oct 22, 2008May 3, 2002none ahead
joint-stock-company-farmak40 open or runningphase 1since Nov 8, 2021Nov 8, 2021none ahead
Laboratorios Silanes S.A. de C.V.40 open or runningphase 4since Jul 15, 2009Jul 15, 2009none ahead
Pfizer40 open or runningphase 1since Dec 15, 2008Jan 25, 2006none ahead
gedeon-richter-plc30 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead
Sun Pharmaceutical Industries30 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead
aet-laboratories-private-limited20 open or runningno phasesince Mar 25, 2022Mar 25, 2022none ahead
agelessrx21 open or runningphase 3since Dec 18, 2024Oct 26, 2020none ahead
aspargo-labs-inc22 open or runningphase 1since Dec 10, 2025Dec 10, 2025none ahead
biocinese20 open or runningphase 4since Jun 2, 2011Apr 27, 2011none ahead
Boryung Pharmaceutical22 open or runningphase 1since Jul 16, 2025Jul 16, 2025none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jul 9, 2010Jul 9, 2010none ahead
Geropharm20 open or runningphase 1since Feb 26, 2018Feb 26, 2018none ahead
Handok20 open or runningphase 4since Sep 21, 2011Sep 21, 2011none ahead
Hoffmann-La Roche20 open or runningphase 3since Aug 29, 2008Aug 29, 2008none ahead
Jeil Pharmaceutical20 open or runningphase 3since Jun 23, 2016Jul 4, 2014none ahead
nusirt-biopharma20 open or runningphase 2since May 28, 2014May 28, 2014none ahead
bio-innova-co-ltd11 open or runningphase 1since Dec 15, 2023Dec 15, 2023none ahead
Clinique Ovo10 open or runningphase 3since Jul 9, 2012Jul 9, 2012none ahead
cortendo-ab10 open or runningphase 1since Mar 18, 2019Mar 18, 2019none ahead
Daewoong Pharmaceutical10 open or runningphase 3since Oct 26, 2016Oct 26, 2016none ahead
dalim-biotech-co-ltd10 open or runningphase 1since Jan 29, 2013Jan 29, 2013none ahead
disphar-international-b-v10 open or runningphase 1since Aug 14, 2014Aug 14, 2014none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Nov 16, 2021Nov 16, 2021none ahead
getz-pharma10 open or runningphase 4since Nov 29, 2021Nov 29, 2021none ahead
Hamad Medical10 open or runningno phasesince Apr 19, 2021Apr 19, 2021none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Jan 23, 2013Jan 23, 2013none ahead
health-clinics-limited10 open or runningphase 3since Jul 22, 2014Jul 22, 2014none ahead
ikfe-cro-gmbh10 open or runningphase 4since Sep 15, 2010Sep 15, 2010none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since May 27, 2020May 27, 2020none ahead
Lotus Pharmaceutical10 open or runningphase 3since Nov 19, 2010Nov 19, 2010none ahead
nabiqasim-industries-pvt-ltd11 open or runningphase 4since Feb 19, 2025Feb 19, 2025none ahead
ozmosis-research-inc10 open or runningphase 2since Feb 18, 2011Feb 18, 2011none ahead
pt-pyridam-farma-tbk10 open or runningno phasesince Feb 12, 2023Feb 12, 2023none ahead

Also a collaborator on its studies: parexel, pt-pharma-metric-labs, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene, Eli Lilly and merck-s-l-spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Oct 5, 2015.

  1. Dec 18, 2024Phase 3 study in Longevityagelessrx · NCT07092618 · 150 planned · United States
  2. Jan 20, 2025Phase 1 study in Diabetes Mellitus, Type 2gedeon-richter-plc · NCT06792968 · 64 enrolled · Russian Federation
  3. Feb 7, 2025Phase 1 study in Diabetes Mellitus, Type 2gedeon-richter-plc · NCT06823856 · 64 enrolled · Russian Federation
  4. Feb 19, 2025nabiqasim-industries-pvt-ltd's first study: phase 4 study in Diabetes MellitusNew to nabiqasim-industries-pvt-ltdnabiqasim-industries-pvt-ltd · NCT06862739 · 800 planned · Pakistan
  5. Jul 16, 2025Boryung Pharmaceutical's first studies: 2 phase 1 studies in Diabetes MellitusNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT07083401, NCT07083388
  6. Aug 12, 2025Phase 1 study in HealthyMerck · NCT07121959 · 14 enrolled · United States
  7. Oct 27, 2025Phase 1 study in HealthyMerck · NCT07222098 · 16 enrolled · United States
  8. Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
  9. Dec 10, 2025aspargo-labs-inc's first studies: 2 phase 1 studies in Healthy VolunteerNew to aspargo-labs-incaspargo-labs-inc · NCT07300033, NCT07300020
  10. Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
  11. Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
  12. Apr 7, 2026Phase 1 study in HealthyMerck · NCT07530289 · 12 enrolled · United States
  13. Jun 3, 2026adium's first studies: 3 no phase studies in Bioequivalence Study in Healthy SubjectsNew to adiumadium · NCT07633054, NCT07633041, NCT07633028
  14. Aug 10, 20264 no phase studiesadium · NCT07763964, NCT07763951, NCT07763912 and 1 more

TargetBeta

“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 215 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07763964Bioequivalance · Mexico–CompletedadiumDec 19, 202546
NCT07763951Bioequivalance · Mexico–CompletedadiumDec 14, 202546
NCT07763912Bioequivalence · Mexico–CompletedadiumDec 5, 202546
NCT07763899Bioequivalance · Mexico–CompletedadiumNov 30, 202546
NCT07633054Bioequivalence Study in Healthy Subjects · Mexico–CompletedadiumNov 24, 202542
NCT07633041Bioequivalence Study in Healthy Subjects · Mexico–CompletedadiumApr 4, 202542
NCT07633028Bioequivalence Study in Healthy Subjects · Mexico–CompletedadiumApr 8, 202542
NCT07530289Healthy · United States1CompletedMerckMay 23, 202612
NCT07396844Fasting · Thailand1CompletedLG ChemJun 26, 202628
NCT07399470Healthy Volunteers · South Korea1CompletedLG ChemFeb 6, 202658
NCT07300033Healthy Volunteer1Not yet recruitingaspargo-labs-incJul 15, 202624
NCT07300020Healthy Volunteer1Not yet recruitingaspargo-labs-incJun 15, 202624
NCT07333742Fed Conditions · South Korea1CompletedLG ChemNov 27, 202550
NCT07222098Healthy · United States1CompletedMerckDec 14, 202516
NCT07121959Healthy · United States1CompletedMerckSep 13, 202514
NCT07083401Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 5, 202640
NCT07083388Diabetes Mellitus · South Korea1RecruitingBoryung PharmaceuticalJul 3, 202652
NCT06862739Diabetes Mellitus · Pakistan4Recruitingnabiqasim-industries-pvt-ltdApr 30, 2026800
NCT06823856Diabetes Mellitus, Type 2 · Russian Federation1Completedgedeon-richter-plcMay 21, 202564
NCT06792968Diabetes Mellitus, Type 2 · Russian Federation1Completedgedeon-richter-plcApr 6, 202564
NCT07092618Longevity · United States3RecruitingagelessrxAug 2025150
NCT06766500Diabetes Mellitus, Type 2 · Russian Federation1Completedgedeon-richter-plcFeb 28, 202564
NCT06233201Healthy Subjects1Not yet recruitingbio-innova-co-ltdJul 14, 202434
NCT06160414Healthy · United Kingdom1CompletedAstraZenecaFeb 5, 202420
NCT05823883DW6014 · Korea, Republic of1UNKNOWNdong-wha-pharmaceutical-co-ltdJul 202330
NCT05823870Healthy Subjects · Korea, Republic of1Completeddong-wha-pharmaceutical-co-ltdMar 6, 202332
NCT05874180Healthy Subjects · Korea, Republic of1Completeddong-wha-pharmaceutical-co-ltdFeb 1, 202331
NCT05874167Healthy Subjects · Korea, Republic of1Completeddong-wha-pharmaceutical-co-ltdOct 11, 202250
NCT05768360Healthy Male Subjects · Germany1CompletedAstraZenecaJun 24, 20236
NCT05753371Drug Use · Indonesia–Completedpt-pyridam-farma-tbkMar 24, 202224
NCT05463094Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyJan 3, 202384
NCT05337969To Determine Bioequivalence Under Fed Conditions–Completedaet-laboratories-private-limitedDec 201560
NCT05329857To Determine Bioequivalence Under Fed Conditions–Completedaet-laboratories-private-limitedJan 201660
NCT05167513Diabetes Mellitus, Type 2 · Pakistan4Completedgetz-pharmaApr 28, 2022188
NCT05132023Healthy · Egypt1CompletedGenuine Research Center, EgyptApr 2, 201926
NCT05124730Pharmacokinetics · Czechia1Completedjoint-stock-company-farmakMay 29, 202144
NCT05124717Pharmacokinetics · Czechia1Completedjoint-stock-company-farmakJul 3, 201928
NCT05123781Pharmacokinetics · Czechia1Completedjoint-stock-company-farmakApr 17, 201928
NCT05125575Pharmacokinetics · Czechia1Completedjoint-stock-company-farmakJan 19, 201928
NCT05064488Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyDec 10, 202140
NCT04899349Breast Neoplasms · United States, Malaysia2TerminatedNovartisMay 10, 20232
NCT04855513Pre-Eclampsia · Qatar–UNKNOWNHamad MedicalApr 24, 2023414
NCT04841096Diabetes Mellitus, Type 2 · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Mar 15, 2024162
NCT04684420Diabetes Mellitus · Korea, Republic of1CompletedMerck KGaA, Darmstadt, GermanyMar 11, 202281
NCT04604678COVID-19 · United States2WithdrawnagelessrxAug 20210
NCT04428086Solid Tumor, Adult · China1CompletedJiangsu HengRui MedicineAug 22, 202119
NCT04317703Diabetes Mellitus, Type 2 · Thailand1CompletedLG ChemSep 5, 202040
NCT04231435Healthy Volunteers · United States1CompletedBristol-Myers SquibbFeb 19, 202024
NCT04050098Type2 Diabetes1UNKNOWNLG ChemNov 30, 201924
NCT03880825Healthy Subjects · United States1Completedcortendo-abMay 3, 201932
NCT03826602Drug-drug Interaction · United States1CompletedPfizerMar 8, 201918
NCT03593707Healthy Volunteers · Belgium1CompletedPfizerJan 17, 201918
NCT03566810Diabetes Mellitus · China1CompletedMerck KGaA, Darmstadt, GermanyNov 28, 201854
NCT03467971Healthy · Mexico1CompletedMerck KGaA, Darmstadt, GermanyApr 22, 201821
NCT03467945Healthy · Germany1CompletedMerck KGaA, Darmstadt, GermanyApr 29, 201840
NCT03458208Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation1CompletedGeropharmMar 2, 201718
NCT03452306Lecithin Cholesterol Acyltransferase Deficiency · Russian Federation1CompletedGeropharmJul 22, 201728
NCT03393208Diabetes Mellitus · China1CompletedMerck KGaA, Darmstadt, GermanyJan 29, 201844
NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil1CompletedAstraZenecaMay 22, 2018284
NCT03787017Healthy Volunteers · Korea, Republic of1CompletedHandokAug 201436

How it is read

Names in the registry

  • “Metformin”, 95 entries
  • “metformin”, 33 entries
  • “Metformin XR”, 11 entries
  • “Fenofibrate /Metformin”, 6 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: EFB0027.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.